{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:09:42Z","timestamp":1792512582163,"version":"4.5.0"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"vor","delay-in-days":206,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/100008561","name":"Burnet Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008561","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of the International AIDS Society"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Introduction<\/jats:bold>: HIV pre\u2010exposure prophylaxis (PrEP) has emerged as a key component of contemporary HIV combination prevention strategies. To explore the local suitability of PrEP, country\u2010specific acceptability studies are needed to inform potential PrEP implementation. In the context of Myanmar, in addition to resource constraints, HIV service access by gay men, other men who have sex with men, and transgender women (GMT) continues to be constrained by legislative and community stigma and marginalization. We aimed to determine PrEP acceptability among GMT in Myanmar and explore the factors associated with willingness to use PrEP.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold>: GMT were recruited in Yangon and Mandalay through local HIV prevention outreach programmes in November and December 2014. Quantitative surveys were administered by trained peer educators and collected data on demographics, sexual risk, testing history and PrEP acceptability. A modified six\u2010item PrEP acceptability scale classified self\u2010reported HIV undiagnosed GMT as willing to use PrEP. Multivariable logistic regression identified factors associated with willingness to use PrEP.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold>: Among 434 HIV undiagnosed GMT, PrEP awareness was low (5%). PrEP acceptability was high, with 270 (62%) GMT classified as willing to use PrEP. GMT recruited in Mandalay (adjusted odds ratio (aOR)\u00a0=\u00a01.79; 95%CI\u00a0=\u00a01.05\u20133.03), who perceived themselves as likely to become HIV positive (aOR\u00a0=\u00a01.82; 95%CI\u00a0=\u00a01.10\u20133.02), who had more than one recent regular partner (aOR\u00a0=\u00a02.94; 95%CI\u00a0=\u00a01.41\u20136.14), no regular partners (aOR\u00a0=\u00a02.05; 95%CI\u00a0=\u00a01.10\u20133.67), more than five casual partners (aOR\u00a0=\u00a02.05; 95%CI\u00a0=\u00a01.06\u20133.99) or no casual partners (aOR\u00a0=\u00a02.25; 95%CI\u00a0=\u00a01.23\u20134.11) were more likely to be willing to use PrEP. The association between never or only occasionally using condoms with casual partners and willingness to use PrEP was marginally significant (aOR\u00a0=\u00a02.02; 95%CI\u00a0=\u00a01.00\u20134.10). GMT who reported concern about side effects and long\u2010term use of PrEP were less likely (aOR\u00a0=\u00a00.35; 95%CI\u00a0=\u00a00.21\u20130.59) to be willing to use PrEP.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold>: This is the first study to assess PrEP acceptability in Myanmar. Findings suggest PrEP is an acceptable prevention option among GMT in Myanmar, providing they are not required to pay for it. Implementation\/demonstration projects are needed to explore the feasibility and cost\u2010effectiveness of PrEP as a prevention option for GMT in Myanmar.<\/jats:p>","DOI":"10.7448\/ias.20.1.21885","type":"journal-article","created":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T18:36:47Z","timestamp":1500748607000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Willingness to use HIV pre\u2010exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar"],"prefix":"10.1002","volume":"20","author":[{"given":"Bridget L.","family":"Draper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaw Min","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaw Win","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poe Poe","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Thant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stoov\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization Consolidated guidelines on HIV prevention diagnosis treatment and care for key populations.2014. Available from:http:\/\/www.who.int\/hiv\/pub\/guidelines\/keypopulations\/en\/"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu916"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70847-3"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ778"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61127-7"},{"key":"e_1_2_10_12_1","unstructured":"World Health Organization Guideline on when to start antiretroviral therapy and on pre\u2010exposure prophylaxis for HIV.2015. Available from:http:\/\/www.who.int\/hiv\/pub\/guidelines\/earlyrelease\u2010arv\/en\/"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2014.0315"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2016.1178703"},{"issue":"3","key":"e_1_2_10_15_1","first-page":"207","article-title":"Who would use PrEP?","volume":"89","author":"Aghaizu A","year":"2013","journal-title":"Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000287"},{"issue":"8","key":"e_1_2_10_17_1","first-page":"955","article-title":"What do Dutch MSM think of preexposure prophylaxis to prevent HIV\u2010infection?","volume":"29","author":"Bil JP","year":"2015","journal-title":"A cross\u2010sectional study. Aids"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-012-0188-z"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2012.0412"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032329"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-016-1516-5"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1545109712473650"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151716"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/2325957413488184"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076650"},{"issue":"1","key":"e_1_2_10_26_1","first-page":"e54288","article-title":"Are Thai MSM willing to take PrEP for HIV prevention?","volume":"8","author":"Wheelock A","year":"2013","journal-title":"An analysis of attitudes, preferences and acceptance. PLoS One"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2011-050312"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064038"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2012.748871"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000037"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61022-8"},{"key":"e_1_2_10_32_1","unstructured":"World Health Organization WHO\/UNAIDS consultation on the ethics of PrEP and early initiation of ART for prevention: how should countries reach a decision? Meeting Report March 2013. Retrieved from:http:\/\/www.who.int\/hiv\/pub\/prep\/ethics_prep\/en\/"},{"key":"e_1_2_10_33_1","unstructured":"UNAIDS and AIDS Data Hub Myanmar Country Snapshot 2016.2017. Available from:http:\/\/aidsdatahub.org\/sites\/default\/files\/country_review\/UNAIDS_snapshot_2016_Myanmar_2017.pdf"},{"key":"e_1_2_10_34_1","unstructured":"National AIDS Programme Global AIDS Response Progress Report Myanmar 2015."},{"key":"e_1_2_10_35_1","unstructured":"UNAIDS.Seminar on responding to sexual diversity: collaboration for HIV response among MSM (MSM) and Transgender Persons (TG) in Myanmar.2015."},{"key":"e_1_2_10_36_1","unstructured":"Myanmar National Strategic Plan on HIV and AIDS 2016 \u2013 2020. Yangon: Ministry of Health and Sports of Myanmar;2017."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1355\/sj28-2c"},{"key":"e_1_2_10_38_1","unstructured":"WorldBank.Gross national income by capita 2015 (atlas method and PPP). 2015. Available from:http:\/\/databank.worldbank.org\/data\/download\/GNIPC.pdf."},{"key":"e_1_2_10_39_1","unstructured":"McLaughlinT Hla TunA(2015 August 29).Myanmar sets $2.80 daily minimum wage in bid to boost investment.Reuters Business News. Retrieved from:http:\/\/www.reuters.com\/article\/us\u2010myanmar\u2010economy\u2010wages\u2010idUSKCN0QY0A620150829"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-014-9646-3"},{"key":"e_1_2_10_41_1","unstructured":"CDC and US Public Health Service.Preexposure prophylaxis for the prevention of HIV infection in the USA\u20142014: A clinical practice guideline. CDC U.S. Department of Health & Human Services;2014."},{"key":"e_1_2_10_42_1","unstructured":"Myanmar National Strategic Plan on HIV and AIDS 2011\u20102015. Yangon: Ministry of Health and Sports;2011."},{"key":"e_1_2_10_43_1","unstructured":"Datta JP (2016 May 23).Cipla gets approval to sell its version of Truvada in India. The Hindu Business Line. Available from:http:\/\/www.thehindubusinessline.com\/companies\/cipla\u2010gets\u2010approval\u2010to\u2010sell\u2010its\u2010version\u2010of\u2010truvada\u2010in\u2010india\/article8637483.ece"},{"key":"e_1_2_10_44_1","unstructured":"Colby D. et al.Safety and efficacy of tenofovir disoproxil fumarate plus emtricitabine for HIV pre\u2010exposure prophylaxis in Thailand. in Asia Pacific Conference on AIDS and Co\u2010infections. 2016. Hong Kong."},{"key":"e_1_2_10_45_1","unstructured":"Medicins Sans Frontieres.Untangling the Web of antiretroviral price reductions:17th Edition July2014 in Access Campaign. 2014. Available from:https:\/\/www.msfaccess.org\/content\/untangling\u2010web\u2010antiretroviral\u2010price\u2010reductions\u201017th\u2010edition\u2010%E2%80%93\u2010july\u20102014"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu012"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","unstructured":"ZablotskaI GrulichAE PhanuphakN AnandT JanyamS PoonkasetwattanaM et al.PrEP implementation in the Asia\u2010Pacific region: opportunities implementation and barriers.J Int AIDS Soc. 19(6):2016.","DOI":"10.7448\/IAS.19.7.21119"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000605"}],"updated-by":[{"DOI":"10.7448\/ias.20.1.22284","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000}}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.7448%2FIAS.20.1.21885","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.7448\/IAS.20.1.21885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:28:39Z","timestamp":1695562119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.7448\/IAS.20.1.21885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.7448\/IAS.20.1.21885"],"URL":"https:\/\/doi.org\/10.7448\/ias.20.1.21885","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.7448\/IAS.20.1.22284","asserted-by":"object"}]},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2017-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"21885"}}